Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

  • Demirelli, Selami (Department of Cardiology, Erzurum Regional Training and Research Hospital) ;
  • Karakelleoglu, Sule (Department of Cardiology, Faculty of Medicine, Ataturk University) ;
  • Gundogdu, Fuat (Department of Cardiology, Faculty of Medicine, Ataturk University) ;
  • Tas, Muhammed Hakan (Department of Cardiology, Faculty of Medicine, Ataturk University) ;
  • Kaya, Ahmet (Department of Cardiology, Faculty of Medicine Ordu University) ;
  • Duman, Hakan (Department of Cardiology, Rize State Hospital) ;
  • Degirmenci, Husnu (Department of Cardiology, Erzurum Palandoken State Hospital) ;
  • Hamur, Hikmet (Department of Cardiology, Mengucek Gazi Regional Training and Research Hospital) ;
  • Simsek, Ziya (Department of Cardiology, Faculty of Medicine, Ataturk University)
  • Published : 2013.07.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: The aim of this study was to investigate the impact of treatment with oral trimetazidine (TMZ) applied before and after percutaneous coronary interventions (PCI) on short-term left ventricular functions and plasma brain natriuretic peptide (BNP) levels in patients with non-ST segment elevation myocardial infarction (NSTEMI) undergoing PCI. Subjects and Methods: The study included 45 patients who were undergoing PCI with the diagnosis of NSTEMI. The patients were randomized into two groups. The first group (n=22) of the patients hospitalized with the diagnosis of NSTEMI was given conventional therapy plus 60 mg TMZ just prior to PCI. Treatment with TMZ was continued for one month after the procedure. TMZ treatment was not given to the second group (n=23). Echocardiography images were recorded and plasma BNP levels were measured just prior to the PCI and on the 1st and 30th days after PCI. Results: The myocardial performance index (MPI) was greater in the second group (p=0.02). In the comparison of BNP levels, they significantly decreased in both of the groups during the 30-day follow-up period ($29.0{\pm}8$ and $50.6{\pm}33$, p<0.01 respectively). However, decreasing of BNP levels was higher in the group administered with TMZ. The decrease of left ventriclular end-diastolic volume was observed in all groups at 30 days after intervention, but was higher in the group administered with TMZ (p=0.01). Conclusion: Trimetazidine treatment commencing prior to PCI and continued after PCI in patients with NSTEMI provides improvements in MPI, left ventricular end diastolic volume and a decrease in BNP levels.

Keywords

References

  1. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267-74. https://doi.org/10.1053/euhj.2001.2896
  2. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998;30:A112.
  3. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21:128-35. https://doi.org/10.1097/00005344-199301000-00019
  4. American Heart Association. 1999 heart and stroke statistical update. Chicago: American Heart Association;1999.
  5. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000;342:1163-70. https://doi.org/10.1056/NEJM200004203421603
  6. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98: 14J-8J.
  7. Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007;120:79-84. https://doi.org/10.1016/j.ijcard.2006.08.082
  8. Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 1991;4:909-12. https://doi.org/10.1093/ajh/4.11.909
  9. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9. https://doi.org/10.1161/01.CIR.87.2.464
  10. White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2003;42:1917-20. https://doi.org/10.1016/j.jacc.2003.09.006
  11. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40:437-45. https://doi.org/10.1016/S0735-1097(02)01986-1
  12. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20:1447-54. https://doi.org/10.1185/030079904X2637
  13. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8. https://doi.org/10.1161/01.RES.86.5.580
  14. Banach M. The role of trimetazidine in the treatment of heart diseases. Ponzan, Poland: Termedia Publishing House;2006. p.52-6.
  15. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002;45:69-72. https://doi.org/10.1006/phrs.2001.0905
  16. Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007;75:536-45. https://doi.org/10.1016/j.cardiores.2007.04.025
  17. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11:615-29. https://doi.org/10.1517/13543784.11.5.615
  18. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8. https://doi.org/10.1016/j.jacc.2006.03.060
  19. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7:143-50. https://doi.org/10.2165/00129784-200707020-00006

Cited by

  1. Trimetazidine and Cardioprotection : Facts and Perspectives vol.66, pp.3, 2013, https://doi.org/10.1177/0003319714530040
  2. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis vol.10, pp.9, 2013, https://doi.org/10.1371/journal.pone.0137775
  3. Trimetazidine in the Prevention of Tissue Ischemic Conditions vol.70, pp.4, 2013, https://doi.org/10.1177/0003319718780551
  4. Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis vol.72, pp.6, 2013, https://doi.org/10.1177/0003319720987745